University of Groningen

Health economics of direct oral anticoagulants in the Netherlands

de Jong, Lisa

DOI:
[10.33612/diss.129441687](https://doi.org/10.33612/diss.129441687)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
de Jong, L. (2020). *Health economics of direct oral anticoagulants in the Netherlands*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.129441687>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Health economics of direct oral anticoagulants in the Netherlands

Lisa de Jong

© by Lisa de Jong. No part of this book may be reproduced or transmitted in any form or by any means without prior written permission of the author.

Financial support for printing of this thesis was provided by the University of Groningen and the Graduate School for Science and Engineering (GSSE).

Cover design:	Rita Lentz en Sander de Jong
Layout and design:	Sanne Kassenberg persoonlijkproefschrift.nl
Printing:	Ridderprint www.ridderprint.nl

rijksuniversiteit
 groningen

Health economics of direct oral anticoagulants in the Netherlands

Proefschrift

ter verkrijging van de graad van doctor aan de
 Rijksuniversiteit Groningen
 op gezag van de
 rector magnificus prof. dr. C. Wijmenga
 en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

vrijdag 2 oktober 2020 om 14.30 uur

door

Lisa Aniek de Jong

geboren op 27 november 1992
 te Groningen

Promotor

Prof. dr. M.J. Postma

Copromotor

Dr. M. van Hulst

Beoordelingscommissie

Prof. dr. K. Meijer

Prof. dr. B. Wilffert

Prof. dr. L. Mantovani

Paranimfen

Anneke Schrik

Anouk van Ochten

Table of contents

Chapter 1	Introduction	7
Part I:	Health economic outcomes in patients with atrial fibrillation	21
Chapter 2	Rivaroxaban for atrial fibrillation in the Netherlands: a real-world data based cost-effectiveness analysis. <i>J Med Econ</i> 2019 Apr 22(4):306-318	23
Chapter 3	Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. <i>PloS One</i> . 2019 Sep; 14(9):e0222658	41
Chapter 4	Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. <i>Eur J Health Econ</i> . 2018 Sep;19(7):957-965.	77
Part II:	Health economic outcomes in patients with venous thromboembolism	99
Chapter 5	Dabigatran for the treatment and secondary prevention of venous thromboembolism: a cost-effectiveness analysis for the Netherlands. <i>PloS One</i> 2016 Oct 24;11(10):e0163550	101
Chapter 6	Costs-effectiveness analysis for apixaban in the acute treatment and prevention of venous thromboembolism in the Netherlands. <i>Clin Ther</i> 2017 Feb;39(2):288-302	129
Chapter 7	Extended treatment with apixaban for venous thromboembolism prevention in the Netherlands: clinical and economic effects. <i>TH Open</i> 2018 Sep 26;2(3):e315-e324	155
Chapter 8	Rivaroxaban for venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis. <i>J Med Econ</i> 2019 Apr 22(4):306-318	179
Chapter 9	Cost-effectiveness analysis and budget impact of rivaroxaban in cancer patients at risk of recurrent venous thromboembolism. <Submitted>	195
Chapter 10	Discussion	221
Appendices	Summary	240
	Nederlandse samenvatting (Dutch summary)	243
	Dankwoord (Acknowledgements)	247
	Curriculum Vitae	251
	List of publications	252